EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease

Wolfgang H Jost, Jaime Kulisevsky, Peter A LeWitt

Journal of Neural Transmission · 2023

DOI: 10.1007/s00702-023-02636-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neural Transmission, 2023. Verfasst von Wolfgang H Jost und 2 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson-Klinik Ortenau, Kreuzbergstr. 12-16, 77709, Wolfach, Germany. w.jost@parkinson-klinik.de. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson's disease (PD) is a neurodegenerative disorder that leads to the degeneration of dopaminergic neurons resulting in a widespread pathology of motor and non-motor symptoms. Oral levodopa remains the most effective symptomatic treatment of PD, but motor complications such as Off episodes occur over time. The spectrum of manifestation of OFF episodes varies, e.g., early morning akinesia, end-of-dose wearing OFF, delayed ON, suboptimal ON and dose failure. The functional disability substantially impacts the quality of life for PD patients. An innovative on-demand therapy to treat Off episodes was approved for patients receiving oral levodopa/dopa deacarboxylase inhibitor: inhaled levodopa powder (Inbrija®). The pulmonary delivery of inhaled levodopa powder provides a predictable and fast treatment effect, independent of gastrointestinal dysfunctions or food intake, which could affect levodopa absorption. Levodopa is administered with a breath-actuated inhaler device and the approved dose is 84 mg per Off episode. During the pivotal SPAN-PD phase III trial, significant improvement in Unified Parkinson Disease Rating Scale III score was measured 30 min post-dose at week 12. Improvement was already seen for the first measured time point 10 min post-dose. No differences in pulmonary function was observed when using inhaled levodopa powder regularly for up to 12 months. Inhaled levodopa powder was also approved for early morning Off episodes. The aim of this review article is to give an overview of the different clinical studies of the innovative inhaled levodopa powder, a new on-demand therapy to treat Off episodes in PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevodopaParkinson DiseaseHumansAntiparkinson AgentsPowdersQuality of LifeAdministration, Inhalation

Stichwörter der Autor:innen

CVT-301End-of-doseInhaled levodopa powderOFF-episodesOn-demand therapyParkinson's disease

Substanzen

LevodopaAntiparkinson AgentsPowders

Autor:innen und Institutionen

  • Parkinson-Klinik Ortenau, Kreuzbergstr. 12-16, 77709, Wolfach, Germany. w.jost@parkinson-klinik.de.
  • Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain.
  • Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain.
  • Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Wayne State University School of Medicine (Sastry Foundation Endowed Chair in Neurology and Henry Ford Hospital), Detroit, MI, 48201, USA.

Zitieren

APA

Jost, W. H., Kulisevsky, J., & LeWitt, P. A. (2023). Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease. Journal of Neural Transmission. https://doi.org/10.1007/s00702-023-02636-3

Vancouver

Jost WH, Kulisevsky J, LeWitt PA. Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease. Journal of Neural Transmission. 2023. doi:10.1007/s00702-023-02636-3

BibTeX
@article{Jost2023,
  author = {Jost, Wolfgang H and Kulisevsky, Jaime and LeWitt, Peter A},
  title = {Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease},
  journal = {Journal of Neural Transmission},
  year = {2023},
  doi = {10.1007/s00702-023-02636-3}
}
Kostenlos starten →